Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Related Concept Videos

Pharmacokinetics in Pediatric Patients: Drug Metabolism

Pharmacokinetics in Pediatric Patients: Drug Metabolism

In pediatric care, understanding the nuances of hepatic drug metabolism is crucial, as it significantly differs from that of adults. This divergence is primarily due to the developmental stage of drug-metabolizing enzymes, which affects how medications are processed in the body. In neonates, for instance, the activity of Phase I enzymes—critical for the initial breakdown of drugs—is markedly reduced, functioning at just 20–40% of the levels seen in adults. This reduction poses a challenge in...

Pharmacokinetics in Pediatric Patients: Drug Distribution

Pharmacokinetics in Pediatric Patients: Drug Distribution

Drug distribution in the pediatric population exhibits unique challenges and considerations due to the physiological differences between children, particularly neonates and infants, and adults. A crucial aspect of pediatric pharmacology is understanding how these differences impact the pharmacokinetics of various drugs, necessitating age-specific dosing strategies to ensure efficacy and safety.Neonates and infants have a higher total body water content, ~75%–90% of their body weight, compared...

Pharmacokinetics in Pediatric Patients: Overview and Drug Absorption

Pharmacokinetics in Pediatric Patients: Overview and Drug Absorption

Understanding the physiological differences in the pediatric population is crucial for effective pharmacotherapy. Neonates, infants, and children exhibit significant variations in gastric pH, gastric emptying time, intestinal transit time, and biliary function. These variations profoundly affect oral drug absorption, necessitating a nuanced approach to pediatric dosing.Neonates present with a unique physiological profile, having a gastric pH greater than 4 and faster and more irregular gastric...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same author

Limiting Albuterol Use by EMS at the Start of the COVID-19 Pandemic: A Retrospective Analysis of Rapid Deimplementation.

The western journal of emergency medicine·2025

Same author

Physiological Impacts of Cold Conditions during Moderate Intensity Activity while Wearing Firefighter Protective Clothing.

Prehospital and disaster medicine·2025

Same author

Simultaneous confidence interval construction for many-to-one of proportion ratios of bilateral correlated data.

PloS one·2024

Same author

Impact of Intravenous Methadone Dosing Schedule on Iatrogenic Withdrawal Syndrome in a Pediatric Intensive Care Unit.

The journal of pediatric pharmacology and therapeutics : JPPT : the official journal of PPAG·2024

Same author

Fixed dose ketamine for prehospital management of hyperactive delirium with severe agitation.

The American journal of emergency medicine·2024

Same author

Interval estimation of relative risks for combined unilateral and bilateral correlated data.

Journal of biopharmaceutical statistics·2024

Search research articles

Related Experiment Video

Updated: Jul 18, 2026

Application of an Amplitude-integrated EEG Monitor (Cerebral Function Monitor) to Neonates

Application of an Amplitude-integrated EEG Monitor (Cerebral Function Monitor) to Neonates

Published on: September 6, 2017

Serum caffeine concentrations in preterm neonates.

Alonso E Concha Leon¹, Kelly Michienzi, Chang-Xing Ma

¹Department of Pediatrics, University at Buffalo, State University of New York, Buffalo, New York, USA.

American Journal of Perinatology

|December 30, 2006

Summary

Caffeine therapy effectively treats apnea of prematurity. Studies show that standard caffeine dosing provides safe and therapeutic serum concentrations in preterm infants, negating the need for routine monitoring.

More Related Videos

Transcutaneous Microcirculatory Imaging in Preterm Neonates

Transcutaneous Microcirculatory Imaging in Preterm Neonates

Published on: December 31, 2015

Assessment and Evaluation of the High Risk Neonate: The NICU Network Neurobehavioral Scale

Assessment and Evaluation of the High Risk Neonate: The NICU Network Neurobehavioral Scale

Published on: August 25, 2014

Related Experiment Videos

Last Updated: Jul 18, 2026

Application of an Amplitude-integrated EEG Monitor (Cerebral Function Monitor) to Neonates

Application of an Amplitude-integrated EEG Monitor (Cerebral Function Monitor) to Neonates

Published on: September 6, 2017

Transcutaneous Microcirculatory Imaging in Preterm Neonates

Transcutaneous Microcirculatory Imaging in Preterm Neonates

Published on: December 31, 2015

Assessment and Evaluation of the High Risk Neonate: The NICU Network Neurobehavioral Scale

Assessment and Evaluation of the High Risk Neonate: The NICU Network Neurobehavioral Scale

Published on: August 25, 2014

Area of Science:

Neonatology
Pharmacology
Pediatrics

Background:

Caffeine therapy is crucial for managing apnea of prematurity and preventing bronchopulmonary dysplasia.
Optimal caffeine dosing regimens and serum concentrations in extremely premature infants remain under investigation.
Current recommendations suggest a 20 mg/kg loading dose followed by a 5 mg/kg/d maintenance dose.

Purpose of the Study:

To determine serum caffeine concentrations in preterm infants receiving 20 or 25 mg/kg loading doses and a 6 mg/kg/d maintenance dose.
To assess the safety and therapeutic range of serum caffeine concentrations within the first 14 postnatal days.
To evaluate the influence of postmenstrual age, weight, and postnatal age on serum caffeine levels.

Main Methods:

A study involving 154 infants with a mean gestational age of 29 weeks.
Serum caffeine concentrations were measured approximately 7 days after initiating therapy.
Analysis included infants with varying gestational ages and clinical parameters of renal and hepatic function.

Main Results:

The 25th to 75th percentile serum caffeine concentration range was 18 to 23 mg/L for both dosing regimens.
Serum caffeine concentrations were consistent and independent of postmenstrual age, weight, or postnatal age within the first 14 days.
Therapeutic and safe serum concentrations were observed across typical ranges of renal and hepatic function.

Conclusions:

Standard caffeine dosing regimens achieve safe and therapeutic serum concentrations in preterm infants (24-35 weeks gestational age).
Routine monitoring of serum caffeine levels is unnecessary unless apnea persists or toxicity is suspected.
Further research may refine dosing for specific subpopulations, but current guidelines appear effective for general use.